These are activated T cells (ATC) coated with anti-CD3 × anti-Her2 bispecific antibodies (Her2Bi) which have antineoplastic and immunomodulating properties. These activated T-cells attach in vivo to the T-cells (CD3-expressing) and the tumor cells (HER2/neu +) thereby cross-linking the T cells with tumor cells. This leads to enhanced immunological response characterized by the recruitment and activation of cytotoxic T lymphocytes (CTLs) and secretion of antitumor cytokines (Yu et al., 2017). This evidence concerns the gene ERBB2 and neoplasm.